InvestSMART

Invex Therapeutics Ltd (ASX: IXC) - Announcements

- Current share price for IXC : $0.105

ASX company news and announcements for Invex Therapeutics Ltd (IXC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Invex Therapeutics Ltd (IXC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Invex Therapeutics Ltd (IXC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Invex Therapeutics Ltd (IXC)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$8 Director Resignations and Appointment of Non-Executive Chair 3 Jul 2023 9:58AM $0.200 $0.105 fallen by 47.50%
$8 Phase III Clinical Trial Update and New IIH Market Analysis 28 Jun 2023 8:40AM $0.455 $0.105 fallen by 76.92%
$8 Invex Granted European Orphan Drug Designation for TBI 23 Jun 2023 8:18AM $0.385 $0.105 fallen by 72.73%
$8 Invex Receives Regulatory Approval for IIH EVOLVE in France 21 Apr 2023 8:17AM $0.445 $0.105 fallen by 76.40%
$8 Quarterly Activities/Appendix 4C Cash Flow Report 20 Apr 2023 8:52AM $0.465 $0.105 fallen by 77.42%
$8 Israel Ministry of Health Approval for IIH EVOLVE 20 Apr 2023 8:12AM $0.465 $0.105 fallen by 77.42%
$8 March Appendix 4C and Investor Conference Call Details 17 Apr 2023 5:34PM $0.440 $0.105 fallen by 76.14%
$8 Notification of cessation of securities - IXC 12 Apr 2023 1:36PM $0.440 $0.105 fallen by 76.14%
$8 German Approval for IIH EVOLVE Phase 3 Clinical Trial 20 Mar 2023 8:11AM $0.450 $0.105 fallen by 76.67%
$8 Publication of Invex IIH Phase II Pressure Trial Results 14 Mar 2023 8:11AM $0.450 $0.105 fallen by 76.67%
$8 Half Year Accounts 17 Feb 2023 9:41AM $0.500 $0.105 fallen by 79%
$8 Quarterly Activities/Appendix 4C Cash Flow Report 25 Jan 2023 8:36AM $0.595 $0.105 fallen by 82.35%
$8 Notification of cessation of securities - IXC 23 Jan 2023 12:00PM $0.600 $0.105 fallen by 82.50%
$8 Notice of Quarterly Investor Call 19 Jan 2023 10:05AM $0.600 $0.105 fallen by 82.50%
$8 First US Clinical Site Activated in IIH EVOLVE Phase III 19 Jan 2023 9:33AM $0.570 $0.105 fallen by 81.58%
$8 Invex Receives Approval for Paediatric Plan from the EMA 14 Dec 2022 9:05AM $0.580 $0.105 fallen by 81.90%
$8 Update - Notification regarding unquoted securities - IXC 8 Dec 2022 4:14PM $0.580 $0.105 fallen by 81.90%
$8 Change of Director's Interest Notice x 4 7 Dec 2022 3:28PM $0.580 $0.105 fallen by 81.90%
$8 Notification regarding unquoted securities - IXC 5 Dec 2022 12:45PM $0.585 $0.105 fallen by 82.05%
$8 Invex to Present at the MST Financial Biotech Forum 30 Nov 2022 1:47PM $0.565 $0.105 fallen by 81.42%
$8 MEDSAFE and Ethics Approval for IIH EVOLVE Trial in NZ 25 Nov 2022 10:04AM $0.595 $0.105 fallen by 82.35%
$8 Investor Presentation 22 Nov 2022 1:05PM $0.550 $0.105 fallen by 80.91%
$8 Results of Meeting 22 Nov 2022 1:03PM $0.550 $0.105 fallen by 80.91%
$8 AGM Presentation 22 Nov 2022 11:38AM $0.550 $0.105 fallen by 80.91%
$8 AGM Chairmans Address 22 Nov 2022 11:33AM $0.550 $0.105 fallen by 80.91%

101 - 125 of 296 results

Page 5 of 12

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.